Evidence map›Paper›PMID 36994542›Full record

ArticleThe EMBO journal2023

LncRNA LITATS1 suppresses TGF-β-induced EMT and cancer cell plasticity by potentiating TβRI degradation.

Chuannan Fan, Qian Wang, Thomas B Kuipers, Davy Cats, Prasanna Vasudevan Iyengar, Sophie C Hagenaars, Wilma E Mesker, Peter Devilee, Rob A E M Tollenaar, Hailiang Mei and 1 more

Abstract read
In one paragraph

Article in The EMBO journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Smoking-Induced STC2Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chuannan FanDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-8754-4913
Qian WangDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-5196-4972
Thomas B KuipersDepartment of Biomedical Data Sciences, Sequencing Analysis Support Core, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-5373-6765
Davy CatsDepartment of Biomedical Data Sciences, Sequencing Analysis Support Core, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-9684-220X
Prasanna Vasudevan IyengarDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-6495-137X
Sophie C HagenaarsDepartment of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.ORCID 0000-0002-9121-1975
Wilma E MeskerDepartment of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.ORCID 0000-0001-5533-4778
Peter DevileeDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-8023-2009
Rob A E M TollenaarDepartment of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.ORCID 0000-0002-6831-6082
Hailiang MeiDepartment of Biomedical Data Sciences, Sequencing Analysis Support Core, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-1781-5508
Peter Ten DijkeDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-7234-342X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial cells acquire mesenchymal phenotypes through epithelial-mesenchymal transition (EMT) during cancer progression. However, how epithelial cells retain their epithelial traits and prevent malignant transformation is not well understood. Here, we report that the long noncoding RNA LITATS1 (LINC01137, ZC3H12A-DT) is an epithelial gatekeeper in normal epithelial cells and inhibits EMT in breast and non-small cell lung cancer cells. Transcriptome analysis identified LITATS1 as a TGF-β target gene. LITATS1 expression is reduced in lung adenocarcinoma tissues compared with adjacent normal tissues and correlates with a favorable prognosis in breast and non-small cell lung cancer patients. LITATS1 depletion promotes TGF-β-induced EMT, migration, and extravasation in cancer cells. Unbiased pathway analysis demonstrated that LITATS1 knockdown potently and selectively potentiates TGF-β/SMAD signaling. Mechanistically, LITATS1 enhances the polyubiquitination and proteasomal degradation of TGF-β type I receptor (TβRI). LITATS1 interacts with TβRI and the E3 ligase SMURF2, promoting the cytoplasmic retention of SMURF2. Our findings highlight a protective function of LITATS1 in epithelial integrity maintenance through the attenuation of TGF-β/SMAD signaling and EMT.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsRNA, Long NoncodingCell Line, TumorCell MovementCell PlasticityEpithelial-Mesenchymal TransitionHumansReceptor, Transforming Growth Factor-beta Type ITransforming Growth Factor betaUbiquitin-Protein LigasesReceptor, Transforming Growth Factor-beta Type IRNA, Long NoncodingSMURF2 protein, humanTransforming Growth Factor betaUbiquitin-Protein Ligasesepithelial-mesenchymal transitionLINC01137TGF-β type I receptortransforming growth factor-βZC3H12A-DT

Identifiers

PMID36994542
PMCPMC10183827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.